Prenetics Global (NASDAQ: PRE) — Company Overview, News & Financial Data
Prenetics Global offers personalized diagnostics and genetics testing, focusing on health insights across various sectors.
Prenetics Global
Prenetics Global (NASDAQ:PRE) is a biotechnology company deeply engaged in revolutionizing the health and wellness industry through personalized diagnostics and genetics testing. With a focus on providing actionable insights for individuals to make informed health decisions, Prenetics operates across multiple sectors including: digital health, precision medicine, and disease prevention. The company's projects range from COVID-19 testing solutions, which gained significant attention during the pandemic, to developing at-home genetic tests that assess risks for certain diseases and conditions. Prenetics aims to democratize access to health data, empowering people globally to take control of their health outcomes with cutting-edge technology and science-backed solutions.
Snapshot
Operations
Products and/or services of Prenetics Global
- CircleDNA - Comprehensive DNA testing kit offering health insights and genetic predispositions.
- ACT Genomics - Precision oncology solutions facilitating cancer treatment and medication planning.
- Prenetics Ecosystem - Integrated health platform enabling access to digital health services and personalized products.
- Project Screen - COVID-19 testing initiative providing PCR tests, rapid antigen tests, and health certifications.
- Oxsed - Rapid airport testing technology designed to detect viruses, including COVID-19, for safer travel.
Prenetics Global executive team
- Sheng Wu YeungCo-Founder, Chairperson & CEO
- Samantha KwokChief of Staff & VP of People & Operations
- Brian ChaeGeneral Counsel
- Senthil Kumar SundaramChief Clinical Officer
- Brian J. RosinChief Financial Officer of U.S.
Key financials
Reported results for Prenetics Global, in USD.
- Market cap
- 315.9M
- Revenue (TTM)
- 154.6M
- P/E ratio
- —
- EPS (diluted, TTM)
- -3.1
- Dividend yield
- —
- Profit margin
- -30.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 92.4M | -38.1M | -37.7M | |
| 30.6M | -48.1M | -46.3M | |
| 21.7M | -51.9M | -62.7M | |
| 13.2M | -66M | -190.5M |